{"mainPropery":{"diseaseId":3829,"diseaseName":"Multiple endocrine neoplasia type 1","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/3829/multiple-endocrine-neoplasia-type-1","synonyms":["MEN1","Endocrine adenomatosis multiple","MEN 1","Wermer syndrome"],"synonyms-with-source":[{"name":"MEN1","source":"OMIM"},{"name":"Endocrine adenomatosis multiple"},{"name":"MEN 1"},{"name":"Wermer syndrome"}],"identifiers":[{"identifierType":"OMIM","identifierId":"131100"},{"identifierType":"ORPHANET","identifierId":"652"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":6,"diseaseTypeName":"Digestive Diseases","source":"Orphanet"},{"diseaseTypeId":8,"diseaseTypeName":"Endocrine Diseases","source":"Orphanet"},{"diseaseTypeId":28,"diseaseTypeName":"Hereditary Cancer Syndromes"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":638,"resourceName":"Association for Multiple Endocrine Neoplasia Disorders (AMEND)","abbreviation":"UK, New Zealand, and USA","address1":"The Warehouse","address2":"No 1 Draper Street","address3":"Southborough","address4":"Tunbridge Wells Kent TN4 0PG","address5":"","city":"","state":"","zip":"","country":"United Kingdom","phone":"+ 44 (0)1892 516076","tty":"","tollFree":"","fax":"","email":"info@amend.org.uk","url":"http://www.amend.org.uk","freeText":""},{"resourceID":2417,"resourceName":"American Multiple Endocrine Neoplasia Support","abbreviation":"","address1":"1027 Hampshire Drive","address2":"","address3":"","address4":"","address5":"","city":"Maryville","state":"TN","zip":"37801","country":"","phone":"865-238-5842","tty":"","tollFree":"","fax":"","email":"http://amensupport.org/contact%20us","url":"http://www.amensupport.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/131100' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?itool=omim_Detailed&DbFrom=omim&Cmd=Link&LinkName=omim_pubmed_calculated&IdsFromResult=131100' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Multiple endocrine neoplasia type 1. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Multiple+endocrine+neoplasia+type+1%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Multiple endocrine neoplasia type 1. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition=multipleendocrineneoplasia' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Multiple endocrine neoplasia type 1. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":336,"resourceId":1154,"resourceName":"RareConnect","descriptionText":"<div style=\"margin-top: 0px; margin-bottom: 0px;\"><a href='https://www.rareconnect.org/en/community/multiple-endocrine-neoplasia' target='_blank'>RareConnect</a> has an online community for patients&nbsp;and families with this condition so they can connect with others and share&nbsp;their experiences living with a rare disease.&nbsp;The project is a joint collaboration between EURORDIS (European Rare Disease Organisation) and NORD (National Organization for Rare Disorders).</div>","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://rarediseases.org/rare-disease-information/rare-diseases/byID/1229/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/000398.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1093723-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=652' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1538/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1561,"resourceId":1316,"resourceName":"National Endocrine and Metabolic Diseases Information Service","descriptionText":"The <a href='http://www.endocrine.niddk.nih.gov/pubs/men1/men1.htm' target='_blank'>National Endocrine and Metabolic Diseases Information Service</a>, a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), provides information on this topic.  Click on the link to view the information on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1700,"resourceId":2173,"resourceName":"Merck Manual","descriptionText":"The&nbsp;<a href='http://www.merckmanuals.com/professional/endocrine_and_metabolic_disorders/multiple_endocrine_neoplasia_men_syndromes/multiple_endocrine_neoplasia_type_1_men_1.html' target='_blank'>Merck Manual</a> for health care professionals provides information on&nbsp;Multiple endocrine neoplasia type 1.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:131100' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":7966,"questionText":"What is multiple endocrine neoplasia, type 1?","answerText":"<strong>Multiple endocrine neoplasia, type 1 (MEN1)</strong> is an inherited condition that causes tumors of the endocrine system (the body's network of hormone-producing glands). People affected by MEN1 typically develop tumors of the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/8890.htm\" target=\"_blank\">parathyroid gland</a>, the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/17227.htm\" target=\"_blank\">pituitary gland</a>, and the pancreas, although other glands may be involved as well. These tumors are often \"functional\" and secrete excess hormones, which can cause a variety of health problems. The most common signs and symptoms of MEN1 are caused by hyperparathyroidism (overactive parathyroid gland) and may include kidney stones; thinning of bones; nausea and vomiting; high blood pressure (hypertension); weakness; and fatigue.[7930] MEN1 is caused by changes (<a href=\"http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/genemutation\" target=\"_blank\">mutations</a>) in the <a href=\"http://ghr.nlm.nih.gov/gene/MEN1\" target=\"_blank\"><em>MEN1</em></a> gene and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant </a>manner. Management for MEN1 usually includes regular screening to allow for early diagnosis and treatment of endocrine tumors.[7931]","dateModified":"2014-11-26T13:35:00"},"basicQuestions":[{"questionId":7990,"questionText":"What are the signs and symptoms of multiple endocrine neoplasia, type 1?","answerText":"Multiple endocrine neoplasia, type 1 (MEN1) is characterized primarily by several different types of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002351.htm\" target=\"_blank\">endocrine</a> tumors. People affected by MEN1 typically develop tumors of the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/8890.htm\" target=\"_blank\">parathyroid gland</a>, the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/17227.htm\" target=\"_blank\">pituitary gland</a>, and the pancreas, although other glands may be involved as well. These tumors are often \"functional\" and secrete excess hormones, which causes many of the different signs and symptoms of the condition. A variety of non-endocrine tumors are also found in MEN1, including lipomas (fatty tumors); and tumors of the skin or the central nervous system (brain and spinal cord).[7931][7930]<br />\r\n<br />\r\nSigns and symptoms of MEN1 vary and largely depend on which endocrine glands are affected:[7931]\r\n<ul>\r\n    <li>Parathyroid tumors are present in 90% of people with MEN1 by age 20-25 years and may cause <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003088.htm\" target=\"_blank\">fatigue</a>, depression, weight loss, constipation, nausea, vomiting, dehydration, kidney stones, fragile bones, and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000468.htm\" target=\"_blank\">hypertension</a>.</li>\r\n    <li>Pituitary tumors can lead to headaches, vision problems, nausea and vomiting. In women, menstrual periods may become irregular or stop completely. Men may have decreased fertility, diminished sexual desire, and/or <a href=\"http://www.nlm.nih.gov/medlineplus/erectiledysfunction.html\" target=\"_blank\">erectile dysfunction</a>.</li>\r\n    <li>Stomach, bowel or pancreas (also called the gastro-entero-pancreatic, or GEP tract) tumors can cause high blood sugar, weight loss, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001053.htm\" target=\"_blank\">glossitis</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000560.htm\" target=\"_blank\">anemia</a>, diarrhea, blood clots, and skin rash.</li>\r\n    <li><a href=\"http://rarediseases.info.nih.gov/gard/5745/adenoma-of-the-adrenal-gland/resources/1\" target=\"_blank\">Adrenal tumors</a> can cause a variety of symptoms depending on the type of hormones they secrete, including high blood pressure, irregular heartbeat, panic attacks, headaches, diabetes, abdominal pain, weakness, excessive hair growth, and stretch marks.</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/carcinoidtumors.html\" target=\"_blank\">Carcinoid tumors</a> (slow-growing tumors that usually begin in the lining of the lungs or the digestive tract can cause flushing of the face and upper chest; diarrhea; and trouble breathing.</li>\r\n</ul>\r\n<br />\r\nThe tumors that develop in MEN1 are often benign; however, in some cases, they can become malignant (cancerous). Gastrinomas (a specific type of GEP tract tumor) and carcinoid tumors are the most likely to advance to cancer.[7931]","dateModified":"2014-12-04T10:13:00","resourceClassificationName":"Symptoms","references":[{"referenceId":7930,"authors":"","articleTitle":"Multiple Endocrine Neoplasia","bookWebsiteJournalTitle":"Genetic Home Reference","date":"August 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/multiple-endocrine-neoplasia","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":7931,"authors":"Pagon RA, Adam MP, Ardinger HH, et al","articleTitle":"Multiple Endocrine Neoplasia Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"September 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1538/?report=printable","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7993,"questionText":"What causes multiple endocrine neoplasia, type 1?","answerText":"Multiple endocrine neoplasia, type 1 (MEN1) is caused by mutations in the <a href=\"http://ghr.nlm.nih.gov/gene/MEN1\" target=\"_blank\"><em>MEN1</em></a> gene. <em>MEN1</em> is a <a href=\"http://www.genome.gov/Glossary/index.cfm?id=202\" target=\"_blank\">tumor suppressor gene</a> which means that it encodes a protein that helps keep cells from growing and dividing too rapidly or in an uncontrolled way. Changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in <em>MEN1 </em>result in a defective protein that is unable to carry out its normal role. This leads to the development of the many different types of tumors found in MEN1.[7930][7931]","dateModified":"2014-12-04T14:10:00","resourceClassificationName":"Cause","references":[{"referenceId":7930,"authors":"","articleTitle":"Multiple Endocrine Neoplasia","bookWebsiteJournalTitle":"Genetic Home Reference","date":"August 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/multiple-endocrine-neoplasia","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":7931,"authors":"Pagon RA, Adam MP, Ardinger HH, et al","articleTitle":"Multiple Endocrine Neoplasia Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"September 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1538/?report=printable","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7994,"questionText":"How is&nbsp;multiple endocrine neoplasia, type 1 inherited?","answerText":"Multiple endocrine neoplasia, type 1 (MEN1) is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner.[7931] This means that to be affected, a person only needs a change (<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutation</a>) in one copy of the responsible <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a> in each cell. In some cases, an affected person inherits the mutation from an affected parent. Other cases may result from new (<a href=\"http://www.ghr.nlm.nih.gov/glossary=denovomutation\" target=\"_blank\">de novo</a>) mutations in the gene. These cases occur in people with no history of the disorder in their family. A person with MEN1 has a 50% chance with each pregnancy of passing along the altered gene to his or her child.","dateModified":"2014-12-04T14:15:00","resourceClassificationName":"Inheritance","references":[{"referenceId":7931,"authors":"Pagon RA, Adam MP, Ardinger HH, et al","articleTitle":"Multiple Endocrine Neoplasia Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"September 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1538/?report=printable","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7995,"questionText":"Is genetic testing available for multiple endocrine neoplasia, type 1?","answerText":"Yes, genetic testing is available for <a href=\"http://ghr.nlm.nih.gov/gene/MEN1\" target=\"_blank\"><em>MEN1</em></a>, the <a href=\"http://www.genome.gov/Glossary/index.cfm?id=70\" target=\"_blank\">gene</a> known to cause multiple endocrine neoplasia, type 1 (MEN1).[7931] Carrier testing for at-risk relatives and prenatal testing are possible if the disease-causing mutation in the family is known. <br />\r\n<br />\r\nThe <a href=\"https://www.ncbi.nlm.nih.gov/gtr/conditions/C0025267/\" target=\"_blank\">Genetic Testing Registry (GTR)</a> is a centralized online resource for information about genetic tests. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.","dateModified":"2014-12-04T14:19:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":7931,"authors":"Pagon RA, Adam MP, Ardinger HH, et al","articleTitle":"Multiple Endocrine Neoplasia Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"September 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1538/?report=printable","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7996,"questionText":"How is multiple endocrine neoplasia, type 1 diagnosed?","answerText":"A diagnosis of multiple endocrine neoplasia, type 1 (MEN1) is based on the presence of two of the following <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002351.htm\" target=\"_blank\">endocrine</a> tumors: <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/8890.htm\" target=\"_blank\">parathyroid</a> tumors; <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000704.htm\" target=\"_blank\">pituitary</a> tumors; and/or stomach, bowel or pancreas (also called the gastro-entero-pancreatic, or GEP tract) tumors. People with only one of the tumors may also receive a diagnosis of MEN1 if they have other family members with the condition. Identification of a change (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a>) in the <a href=\"http://ghr.nlm.nih.gov/gene/MEN1\" target=\"_blank\"><em>MEN1</em></a> gene can be used to confirm the diagnosis.[7931][7959]<br />\r\n<br />\r\nIn addition to a complete physical exam and medical history, laboratory tests that evaluate the levels of certain hormones in the blood or urine are often used detect the different types of tumors found in MEN1. Imaging studies such as <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003789.htm\" target=\"_blank\">computed tomography (CT scan)</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003335.htm\" target=\"_blank\">magnetic resonance imaging (MRI scan)</a>, and/or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003338.htm\" target=\"_blank\">endoscopic</a> ultrasound may be recommended to confirm the location and size of the tumors. Some people may also need a <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003416.htm\" target=\"_blank\">biopsy</a> of the tumor to confirm the diagnosis.[7931][7959]","dateModified":"2014-12-04T14:38:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":7931,"authors":"Pagon RA, Adam MP, Ardinger HH, et al","articleTitle":"Multiple Endocrine Neoplasia Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"September 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1538/?report=printable","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":7959,"authors":"","articleTitle":"Multiple Endocrine Neoplasia, Type 1","bookWebsiteJournalTitle":"NORD","date":"May 2012","volume":"","pages":"","url":"http://rarediseases.org/rare-disease-information/rare-diseases/byID/1229/viewFullReport","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7999,"questionText":"How might multiple endocrine neoplasia, type 1 be treated?","answerText":"People with multiple endocrine neoplasia, type 1 (MEN1) are usually managed with regular screening to allow for early diagnosis and treatment of endocrine tumors. This screening begins in early childhood and continues for life.[7931]<br />\r\n<br />\r\nRecommended screening includes specific types of imaging studies every 3-5 years:[7931]\r\n<ul>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003791.htm\" target=\"_blank\">Head magnetic resonance imaging (MRI scan)</a> begining at age 5.</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003789.htm\" target=\"_blank\">Abdominal computed tomography (CT scan)</a> or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003796.htm\" target=\"_blank\">abdominal MRI scan</a> beginning at age 20.</li>\r\n</ul>\r\nAnnual blood tests are also recommended, which evaluate the levels of certain substances that can be elevated if an MEN1-associated tumor is present:[7931]\r\n<ul>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003718.htm\" target=\"_blank\">Prolactin</a> concentrations, which can be used to screen for pituitary tumors, are measured beginning at age 5.</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/calcium.html\" target=\"_blank\">Calcium</a> concentrations, which can be used to screen for parathyroid tumors, are measured beginning at age 8.</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003697.htm\" target=\"_blank\">Gastrin</a> concentrations, which can be used to screen for gastrinomas (a specific type of gastro-entero-pancreatic tract tumor) are measured beginning at age 20.</li>\r\n</ul>\r\n<p>When a tumor is detected through screening, the best treatment options depend on many factors, including the size, location, and type of tumor; and whether or not the tumor is \"functional\" (releasing hormones). Many tumors are treated with surgery. If a tumor is functional, removal of the affected endocrine gland often resolves health problems that may be present as a result of elevated hormones. In some cases, functional tumors can be treated with medications that block the function or lower the levels of the overproduced hormone. <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">Chemotherapy</a> or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">radiation therapy</a> may also be used to to shrink or destroy tumors.[7931][7959]</p>","dateModified":"2014-12-04T20:21:00","resourceClassificationName":"Treatment","references":[{"referenceId":7931,"authors":"Pagon RA, Adam MP, Ardinger HH, et al","articleTitle":"Multiple Endocrine Neoplasia Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"September 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1538/?report=printable","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":7959,"authors":"","articleTitle":"Multiple Endocrine Neoplasia, Type 1","bookWebsiteJournalTitle":"NORD","date":"May 2012","volume":"","pages":"","url":"http://rarediseases.org/rare-disease-information/rare-diseases/byID/1229/viewFullReport","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7998,"questionText":"What is the long-term outlook for people with multiple endocrine neoplasia, type 1?","answerText":"The long-term outlook (prognosis) for people with multiple endocrine neoplasia, type 1 (MEN1) varies. Although improved understanding of the signs and symptoms found in MEN1 and early diagnosis and treatment of the characteristic endocrine tumors have improved the prognosis for some MEN1-associated health problems, people with MEN1 have a shortened life expectancy. This is largely due to the risk of some tumors found in MEN1 such as <a href=\"http://www.cancer.gov/dictionary?cdrid=44233\" target=\"_blank\">carcinoid tumors</a> and certain types of gastro-entero-pancreatic (GEP) tract tumors (tumors of the stomach, bowel or pancreas) becoming malignant (cancerous).[7931][7960]","dateModified":"2014-12-04T19:46:00","resourceClassificationName":"Prognosis","references":[{"referenceId":7931,"authors":"Pagon RA, Adam MP, Ardinger HH, et al","articleTitle":"Multiple Endocrine Neoplasia Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"September 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1538/?report=printable","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":7960,"authors":"Andrew Arnold, MD","articleTitle":"Multiple endocrine neoplasia type 1: Treatment","bookWebsiteJournalTitle":"UpToDate","date":"May 22, 2013","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":2754,"phenoTypeName":"Angiofibromas","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":14530,"phenoTypeName":"Hypercalcemia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":5535,"phenoTypeName":"Impairment of activities of daily living","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":1382,"phenoTypeName":"Parathyroid hyperplasia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":1377,"phenoTypeName":"Primary hyperparathyroidism","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13419,"phenoTypeName":"Abdominal pain","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14186,"phenoTypeName":"Adrenocortical abnormality","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11514,"phenoTypeName":"Decreased male libido","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11842,"phenoTypeName":"Galactorrhea","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13410,"phenoTypeName":"Gastroesophageal reflux","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13830,"phenoTypeName":"Hypercalciuria","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":1476,"phenoTypeName":"Hypergastrinemia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14170,"phenoTypeName":"Impotence","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":15058,"phenoTypeName":"Large cafe-au-lait macules with irregular margins","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8292,"phenoTypeName":"Multiple lipomas","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10363,"phenoTypeName":"Peptic ulcer","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":12113,"phenoTypeName":"Pituitary prolactin cell adenoma","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10304,"phenoTypeName":"Reduced bone mineral density","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5059,"phenoTypeName":"Weight loss","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13433,"phenoTypeName":"Zollinger-Ellison syndrome","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":385,"phenoTypeName":"Abnormal circulating aldosterone","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":103,"phenoTypeName":"Adrenocortical carcinoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9734,"phenoTypeName":"Amenorrhea","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13430,"phenoTypeName":"Anorexia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":58,"phenoTypeName":"Confetti-like hypopigmented macules","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9380,"phenoTypeName":"Confusion","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13409,"phenoTypeName":"Constipation","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8739,"phenoTypeName":"Cranial nerve compression","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":15027,"phenoTypeName":"Decreased vigilance","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13042,"phenoTypeName":"Dehydration","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6011,"phenoTypeName":"Depressivity","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13766,"phenoTypeName":"Duodenal ulcer","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9770,"phenoTypeName":"Gingival fibromatosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6022,"phenoTypeName":"Goiter","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6046,"phenoTypeName":"Growth hormone excess","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11409,"phenoTypeName":"Headache","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8049,"phenoTypeName":"Hematemesis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6027,"phenoTypeName":"Hypertension","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13289,"phenoTypeName":"Increased susceptibility to fractures","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4899,"phenoTypeName":"Insulinoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":736,"phenoTypeName":"Intestinal carcinoid","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8721,"phenoTypeName":"Lethargy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11213,"phenoTypeName":"Melena","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":7948,"phenoTypeName":"Meningioma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13408,"phenoTypeName":"Nausea","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14159,"phenoTypeName":"Nephrolithiasis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":7897,"phenoTypeName":"Osteolysis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":12233,"phenoTypeName":"Pituitary growth hormone cell adenoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4687,"phenoTypeName":"Primary hypercortisolism","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4249,"phenoTypeName":"Proportionate tall stature","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14130,"phenoTypeName":"Short attention span","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6282,"phenoTypeName":"Shortened QT interval","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4300,"phenoTypeName":"Thyroid carcinoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13400,"phenoTypeName":"Vomiting","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10601,"phenoTypeName":"Atypical absence status epilepticus","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8702,"phenoTypeName":"Coma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13604,"phenoTypeName":"Elevated calcitonin","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":4299,"phenoTypeName":"Ependymoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":2306,"phenoTypeName":"Glucagonoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":14584,"phenoTypeName":"Increased serum serotonin","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":12125,"phenoTypeName":"Parathyroid carcinoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13292,"phenoTypeName":"Pheochromocytoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":15603,"phenoTypeName":"Pituitary corticotropic cell adenoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":12232,"phenoTypeName":"Pituitary gonadotropic cell adenoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":12234,"phenoTypeName":"Pituitary null cell adenoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":12235,"phenoTypeName":"Pituitary thyrotropic cell adenoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":12005,"phenoTypeName":"Pulmonary carcinoid tumor","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":11702,"phenoTypeName":"Thymoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":14183,"phenoTypeName":"Abnormality of the thyroid gland","percentRanges":"-"},{"phenoTypeId":15147,"phenoTypeName":"Adenoma sebaceum","percentRanges":"-"},{"phenoTypeId":15585,"phenoTypeName":"Adrenocortical adenoma","percentRanges":"-"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":10286,"phenoTypeName":"Cafe-au-lait spot","percentRanges":"-"},{"phenoTypeId":1906,"phenoTypeName":"Carcinoid tumor","percentRanges":"-"},{"phenoTypeId":13401,"phenoTypeName":"Diarrhea","percentRanges":"-"},{"phenoTypeId":124,"phenoTypeName":"Esophagitis","percentRanges":"-"},{"phenoTypeId":13041,"phenoTypeName":"Hypoglycemia","percentRanges":"-"},{"phenoTypeId":14565,"phenoTypeName":"Increased circulating cortisol level","percentRanges":"-"},{"phenoTypeId":6061,"phenoTypeName":"Increased circulating prolactin concentration","percentRanges":"-"},{"phenoTypeId":15588,"phenoTypeName":"Pancreatic islet cell adenoma","percentRanges":"-"},{"phenoTypeId":4306,"phenoTypeName":"Parathyroid adenoma","percentRanges":"-"},{"phenoTypeId":4302,"phenoTypeName":"Pituitary adenoma","percentRanges":"-"},{"phenoTypeId":13932,"phenoTypeName":"Prolactinoma","percentRanges":"-"},{"phenoTypeId":8310,"phenoTypeName":"Subcutaneous lipoma","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Multiple_endocrine_neoplasia_type_1"}